newsfilter
← Latest News
Business Wire·

Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

-- Kaken Pharmaceutical, Co., Ltd. Will Pay Astria Therapeutics Up to $32 Million in Upfront and Milestone Payments, Plus Royalties for Japanese Development and Commercialization Rights Related to Navenibart -- --